ArticleIJTLD open2026
QT prolongation in participants receiving bedaquiline-containing regimens: analysis of data from Phase 3 STREAM Stage 2.
Article in IJTLD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultidrug-resistant TB regimens are associated with higher risk of QT prolongation; understanding bedaquiline's (BDQ) role is crucial for safety and management.
methodsWe report a pre-specified secondary analysis of data from STREAM Stage 2 (ISRCTN18148631), a Phase 3, non-inferiority trial evaluating BDQ-containing regimens in participants aged ≥15 years with multidrug/rifampicin-resistant TB. Participants were randomised to one of four regimens (two BDQ-containing and two BDQ-free). Electrocardiogram assessments were routinely conducted through Week 76, with continued monitoring for significant QT prolongation. Averaged Fridericia's corrected QT interval (QTcF) results are reported.
resultsOf 588 participants, median age was 32.7 years (range 16-69) and 236 (40%) were female. QTcF gradually increased from baseline to Weeks 10-14, plateaued, then decreased during treatment. Mean QTcF change for BDQ regimens was <10 ms higher than control at all timepoints. Risk of experiencing at least one QTcF ≥500 ms was similar between control and 40-week oral BDQ regimen (hazard ratio 1.43, 95% confidence interval: 0.66-3.11).
conclusionBDQ was associated with mean QTcF prolongation of <10 ms, which was not more than additive to other drugs. Rates of QTcF ≥500 ms were comparable between BDQ-containing and BDQ-free arms, indicating comparable incidences of this event within the study context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.